Salarius Pharmaceuticals Inc (SLRX)
NASDAQ:SLRX
Holding SLRX?
Track your performance easily

Salarius Pharmaceuticals (SLRX) Income Statement

491 Followers

Salarius Pharmaceuticals Income Statement

Last quarter (Q2 2024), Salarius Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Salarius Pharmaceuticals's net income was $-1.42M. See Salarius Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 1.84M$ 5.23M$ 3.47M
Cost of Revenue
------
Gross Profit
---$ 1.84M--
Operating Expense
$ 6.74M$ 12.89M$ 31.84M$ -14.65M$ 12.84M$ 11.73M
Operating Income
$ -6.74M$ -12.89M$ -31.84M$ -12.81M$ -7.61M$ -8.26M
Net Non Operating Interest Income Expense
$ 277.68K$ 352.25K$ 218.73K-$ -3.05K$ 15.65K
Other Income Expense
--$ -14.45K$ -44.69K$ 258.55K$ 1.31M
Pretax Income
$ -6.46M$ -12.54M$ -31.64M$ -12.77M$ -7.35M$ -6.94M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -6.46M$ -12.54M$ -31.61M$ -12.77M$ -7.75M$ -6.94M
Basic EPS
$ -2.96$ -3.84$ -14.88$ -7.72$ -0.50$ -2.12
Diluted EPS
$ -2.96$ -3.84$ -14.88$ -7.72$ -0.50$ -2.12
Basic Average Shares
$ 12.75M$ 3.26M$ 2.12M$ 41.37M$ 15.58M$ 3.27M
Diluted Average Shares
$ 12.75M$ 3.26M$ 2.12M$ 41.37M$ 15.58M$ 3.27M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 6.74M$ 12.89M$ 31.84M$ -14.65M$ 12.84M$ 11.73M
Net Income From Continuing And Discontinued Operation
$ -6.46M$ -12.54M$ -31.61M$ -12.77M$ -7.35M$ -6.94M
Normalized Income
$ -5.73M$ -9.91M$ -16.10M-$ -7.61M$ -8.25M
Interest Expense
------
EBIT
$ -6.46M$ -12.89M$ -31.64M$ -12.77M$ -7.61M$ -8.26M
EBITDA
$ -6.46M$ -12.88M$ -31.64M$ -12.75M$ -7.59M$ -8.14M
Currency in USD

Salarius Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis